FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma

This research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR),